

WHAT IS CLAIMED IS:

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36), Figure 20 (SEQ ID NO:45), Figure 22 (SEQ ID NO:52), Figure 24 (SEQ ID NO:59), Figure 26 (SEQ ID NO:64), Figure 28 (SEQ ID NO:69), Figure 30 (SEQ ID NO:74), Figure 33 (SEQ ID NO:85), Figure 35 (SEQ ID NO:90), Figure 37 (SEQ ID NO:97), Figure 39 (SEQ ID NO:102), Figure 41 (SEQ ID NO:109), Figure 43 (SEQ ID NO:114), Figure 45 (SEQ ID NO:119), Figure 47 (SEQ ID NO:124), Figure 49 (SEQ ID NO:132), Figure 51 (SEQ ID NO:137), Figure 53 (SEQ ID NO:145), Figure 55 (SEQ ID NO:150), Figure 59 (SEQ ID NO:157), Figure 61 (SEQ ID NO:162), Figure 63 (SEQ ID NO:169), Figure 66 (SEQ ID NO:178), Figure 68 (SEQ ID NO:183), Figure 70 (SEQ ID NO:190), Figure 73 (SEQ ID NO:196), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:211), Figure 79 (SEQ ID NO:216), Figure 81 (SEQ ID NO:221), Figure 83 (SEQ ID NO:226), Figure 85 (SEQ ID NO:231), Figure 87 (SEQ ID NO:236), Figure 89 (SEQ ID NO:245), Figure 91 (SEQ ID NO:254), Figure 93 (SEQ ID NO:259), Figure 95 (SEQ ID NO:264), Figure 98 (SEQ ID NO:270), Figure 109 (SEQ ID NO:284), Figure 118 (SEQ ID NO:296), Figure 120 (SEQ ID NO:301), Figure 122 (SEQ ID NO:303), Figure 125 (SEQ ID NO:309), Figure 129 (SEQ ID NO:322), Figure 132 (SEQ ID NO:330), Figure 136 (SEQ ID NO:337), Figure 139 (SEQ ID NO:346), Figure 142 (SEQ ID NO:352), Figure 145 (SEQ ID NO:358), Figure 147 (SEQ ID NO:363), Figure 149 (SEQ ID NO:370), Figure 151 (SEQ ID NO:375), Figure 153 (SEQ ID NO:380), Figure 155 (SEQ ID NO:385), Figure 157 (SEQ ID NO:390), Figure 159 (SEQ ID NO:395), Figure 161 (SEQ ID NO:400), Figure 163 (SEQ ID NO:405), Figure 165 (SEQ ID NO:410), Figure 167 (SEQ ID NO:415), Figure 169 (SEQ ID NO:420), Figure 171 (SEQ ID NO:425), Figure 173 (SEQ ID NO:430), Figure 177 (SEQ ID NO:437), Figure 179 (SEQ ID NO:442), Figure 181 (SEQ ID NO:447), Figure 183 (SEQ ID NO:452), Figure 185 (SEQ ID NO:454), Figure 187 (SEQ ID NO:456), Figure 190 (SEQ ID NO:459), Figure 192 (SEQ ID NO:464), Figure 194 (SEQ ID NO:466), Figure 196 (SEQ ID NO:468), Figure 198 (SEQ ID NO:470), Figure 200 (SEQ ID NO:472), Figure 202 (SEQ ID NO:477), Figure 204 (SEQ ID NO:483), Figure 207 (SEQ ID NO:488), Figure 209 (SEQ ID NO:496), Figure 211 (SEQ ID NO:498), Figure 213 (SEQ ID NO:506), Figure 215 (SEQ ID NO:508), Figure 217 (SEQ ID NO:510), Figure 219 (SEQ ID NO:515), Figure 222 (SEQ ID NO:523), Figure 225 (SEQ ID NO:526), Figure 230 (SEQ ID NO:612), Figure 232 (SEQ ID NO:614), Figure 234 (SEQ ID NO:616) and Figure 236 (SEQ ID NO:618).

2. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:6), Figure 8 (SEQ ID NO:18), Figure 10 (SEQ ID NO:27), Figure 14 (SEQ ID NO:35), Figure 19 (SEQ ID NO:44), Figure 21 (SEQ ID NO:51), Figure 23 (SEQ ID NO:58), Figure 25 (SEQ ID NO:63), Figure 27 (SEQ ID NO:68), Figure 29 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:89), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:101), Figure 40 (SEQ ID NO:108), Figure 42 (SEQ ID NO:113), Figure 44 (SEQ ID NO:118), Figure 46 (SEQ ID NO:123), Figure 48 (SEQ ID NO:131), Figure 50 (SEQ ID NO:136), Figure 52 (SEQ ID NO:144), Figure 54 (SEQ ID NO:149), Figure 58 (SEQ ID NO:156), Figure 60

0097816410450120253035

(SEQ ID NO:161), Figure 62 (SEQ ID NO:168), Figure 65 (SEQ ID NO:177), Figure 67 (SEQ ID NO:182), Figure 69 (SEQ ID NO:189), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:205), Figure 76 (SEQ ID NO:210), Figure 78 (SEQ ID NO:215), Figure 80 (SEQ ID NO:220), Figure 82 (SEQ ID NO:225), Figure 84 (SEQ ID NO:230), Figure 86 (SEQ ID NO:235), Figure 88 (SEQ ID NO:244), Figure 90 (SEQ ID NO:253), Figure 92 (SEQ ID NO:258), Figure 94 (SEQ ID NO:263), Figure 97 (SEQ ID NO:269), Figure 108 (SEQ ID NO:283), Figure 117 (SEQ ID NO:295), Figure 119 (SEQ ID NO:300), Figure 121 (SEQ ID NO:302), Figure 124 (SEQ ID NO:308), Figure 128 (SEQ ID NO:321), Figure 131 (SEQ ID NO:329), Figure 135 (SEQ ID NO:336), Figure 138 (SEQ ID NO:345), Figure 141 (SEQ ID NO:351), Figure 144 (SEQ ID NO:357), Figure 146 (SEQ ID NO:362), Figure 148 (SEQ ID NO:369), Figure 150 (SEQ ID NO:374), Figure 152 (SEQ ID NO:379), Figure 154 (SEQ ID NO:384), Figure 156 (SEQ ID NO:389), Figure 158 (SEQ ID NO:394), Figure 160 (SEQ ID NO:399), Figure 162 (SEQ ID NO:404), Figure 164 (SEQ ID NO:409), Figure 166 (SEQ ID NO:414), Figure 168 (SEQ ID NO:419), Figure 170 (SEQ ID NO:424), Figure 172 (SEQ ID NO:429), Figure 176 (SEQ ID NO:436), Figure 178 (SEQ ID NO:441), Figure 180 (SEQ ID NO:446), Figure 182 (SEQ ID NO:451), Figure 184 (SEQ ID NO:453), Figure 186 (SEQ ID NO:455), Figure 189 (SEQ ID NO:458), Figure 191 (SEQ ID NO:463), Figure 193 (SEQ ID NO:465), Figure 195 (SEQ ID NO:467), Figure 197 (SEQ ID NO:469), Figure 199 (SEQ ID NO:471), Figure 201 (SEQ ID NO:476), Figure 203 (SEQ ID NO:482), Figure 206 (SEQ ID NO:487), Figure 208 (SEQ ID NO:495), Figure 210 (SEQ ID NO:497), Figure 212 (SEQ ID NO:505), Figure 214 (SEQ ID NO:507), Figure 216 (SEQ ID NO:509), Figure 218 (SEQ ID NO:514), Figure 221 (SEQ ID NO:522), Figure 224 (SEQ ID NO:525), Figure 229 (SEQ ID NO:611), Figure 231 (SEQ ID NO:613), Figure 233 (SEQ ID NO:615) and Figure 235 (SEQ ID NO:617).

3. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:6), Figure 8 (SEQ ID NO:18), Figure 10 (SEQ ID NO:27), Figure 14 (SEQ ID NO:35), Figure 19 (SEQ ID NO:44), Figure 21 (SEQ ID NO:51), Figure 23 (SEQ ID NO:58), Figure 25 (SEQ ID NO:63), Figure 27 (SEQ ID NO:68), Figure 29 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:89), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:101), Figure 40 (SEQ ID NO:108), Figure 42 (SEQ ID NO:113), Figure 44 (SEQ ID NO:118), Figure 46 (SEQ ID NO:123), Figure 48 (SEQ ID NO:131), Figure 50 (SEQ ID NO:136), Figure 52 (SEQ ID NO:144), Figure 54 (SEQ ID NO:149), Figure 58 (SEQ ID NO:156), Figure 60 (SEQ ID NO:161), Figure 62 (SEQ ID NO:168), Figure 65 (SEQ ID NO:177), Figure 67 (SEQ ID NO:182), Figure 69 (SEQ ID NO:189), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:205), Figure 76 (SEQ ID NO:210), Figure 78 (SEQ ID NO:215), Figure 80 (SEQ ID NO:220), Figure 82 (SEQ ID NO:225), Figure 84 (SEQ ID NO:230), Figure 86 (SEQ ID NO:235), Figure 88 (SEQ ID NO:244), Figure 90 (SEQ ID NO:253), Figure 92 (SEQ ID NO:258), Figure 94 (SEQ ID NO:263), Figure 97 (SEQ ID NO:269), Figure 108 (SEQ ID NO:283), Figure 117 (SEQ ID NO:295), Figure 119 (SEQ ID NO:300), Figure 121 (SEQ ID NO:302), Figure 124 (SEQ ID NO:308), Figure 128 (SEQ ID NO:321), Figure 131 (SEQ ID NO:329), Figure 135 (SEQ ID NO:336), Figure 138 (SEQ ID NO:345), Figure 141 (SEQ ID NO:351), Figure 144 (SEQ ID NO:357), Figure 146 (SEQ ID NO:362), Figure 148 (SEQ ID NO:369), Figure 150 (SEQ ID NO:374), Figure 152 (SEQ ID NO:379), Figure 154 (SEQ ID NO:384), Figure 156 (SEQ ID

NO:389), Figure 158 (SEQ ID NO:394), Figure 160 (SEQ ID NO:399), Figure 162 (SEQ ID NO:404), Figure 164 (SEQ ID NO:409), Figure 166 (SEQ ID NO:414), Figure 168 (SEQ ID NO:419), Figure 170 (SEQ ID NO:424), Figure 172 (SEQ ID NO:429), Figure 176 (SEQ ID NO:436), Figure 178 (SEQ ID NO:441), Figure 180 (SEQ ID NO:446), Figure 182 (SEQ ID NO:451), Figure 184 (SEQ ID NO:453), Figure 186 (SEQ ID NO:455), Figure 189 (SEQ ID NO:458), Figure 191 (SEQ ID NO:463), Figure 193 (SEQ ID NO:465), Figure 195 (SEQ ID NO:467), Figure 197 (SEQ ID NO:469), Figure 199 (SEQ ID NO:471), Figure 201 (SEQ ID NO:476), Figure 203 (SEQ ID NO:482), Figure 206 (SEQ ID NO:487), Figure 208 (SEQ ID NO:495), Figure 210 (SEQ ID NO:497), Figure 212 (SEQ ID NO:505), Figure 214 (SEQ ID NO:507), Figure 216 (SEQ ID NO:509), Figure 218 (SEQ ID NO:514), Figure 221 (SEQ ID NO:522), Figure 224 (SEQ ID NO:525), Figure 229 (SEQ ID NO:611), Figure 231 (SEQ ID NO:613), Figure 233 (SEQ ID NO:615) and Figure 235 (SEQ ID NO:617).

4. Isolated nucleic acid having at least 80 % nucleic acid sequence identity to the full-length coding sequence of the DNA deposited under ATCC accession number ATCC 209791, ATCC 209786, ATCC 209788, ATCC 209787, ATCC 209789, ATCC 209617, ATCC 209620, ATCC 209616, ATCC 209679, ATCC 209654, ATCC 209655, ATCC 209656, ATCC 209721, ATCC 209717, ATCC 209716, ATCC 209722, ATCC 209668, ATCC 209670, ATCC 209718, ATCC 209784, ATCC 209703, ATCC 209808, ATCC 209810, ATCC 209699, ATCC 209811, ATCC 209813, ATCC 209705, ATCC 209806, ATCC 209809, ATCC 209805, ATCC 209812, ATCC 209844, ATCC 209847, ATCC 209845, ATCC 209843, ATCC 209846, ATCC 209750, ATCC 209848, ATCC 209851, ATCC 209754, ATCC 209747, ATCC 209861, ATCC 209862, ATCC 209867, ATCC 209879, ATCC 209868, ATCC 209869, ATCC 209775, ATCC 209772, ATCC 209774, ATCC 209777, ATCC 209905, ATCC 209855, ATCC 209910, ATCC 209424, ATCC 209720, ATCC 209714, ATCC 209785, ATCC 209911, ATCC 209669, ATCC 209704, ATCC 209702, ATCC 209701, ATCC 209700, ATCC 209814, ATCC 209715, ATCC 209807, ATCC 209753, ATCC 209749, ATCC 209748, ATCC 209842, ATCC 209849, ATCC 209880, ATCC 209864, ATCC 209882, ATCC 209883, ATCC 209865, ATCC 209866, ATCC 209857, ATCC 209870, ATCC 209859, ATCC 209653, ATCC 209389, ATCC 209386, ATCC 203242, ATCC 203243, ATCC 209783, ATCC 209487, ATCC 209680, 240-PTA or ATCC 209773.

5. A vector comprising the nucleic acid of any one of Claims 1 to 4.

6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.

7. A host cell comprising the vector of Claim 5.

8. The host cell of Claim 7, wherein said cell is a CHO cell.

9. The host cell of Claim 7, wherein said cell is an *E. coli*.

10. The host cell of Claim 7, wherein said cell is a yeast cell.

11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

12. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36), Figure 20 (SEQ ID NO:45), Figure 22 (SEQ ID NO:52), Figure 24 (SEQ ID NO:59), Figure 26 (SEQ ID NO:64), Figure 28 (SEQ ID NO:69), Figure 30 (SEQ ID NO:74), Figure 33 (SEQ ID NO:85), Figure 35 (SEQ ID NO:90), Figure 37 (SEQ ID NO:97), Figure 39 (SEQ ID NO:102), Figure 41 (SEQ ID NO:109), Figure 43 (SEQ ID NO:114), Figure 45 (SEQ ID NO:119), Figure 47 (SEQ ID NO:124), Figure 49 (SEQ ID NO:132), Figure 51 (SEQ ID NO:137), Figure 53 (SEQ ID NO:145), Figure 55 (SEQ ID NO:150), Figure 59 (SEQ ID NO:157), Figure 61 (SEQ ID NO:162), Figure 63 (SEQ ID NO:169), Figure 66 (SEQ ID NO:178), Figure 68 (SEQ ID NO:183), Figure 70 (SEQ ID NO:190), Figure 73 (SEQ ID NO:196), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:211), Figure 79 (SEQ ID NO:216), Figure 81 (SEQ ID NO:221), Figure 83 (SEQ ID NO:226), Figure 85 (SEQ ID NO:231), Figure 87 (SEQ ID NO:236), Figure 89 (SEQ ID NO:245), Figure 91 (SEQ ID NO:254), Figure 93 (SEQ ID NO:259), Figure 95 (SEQ ID NO:264), Figure 98 (SEQ ID NO:270), Figure 109 (SEQ ID NO:284), Figure 118 (SEQ ID NO:296), Figure 120 (SEQ ID NO:301), Figure 122 (SEQ ID NO:303), Figure 125 (SEQ ID NO:309), Figure 129 (SEQ ID NO:322), Figure 132 (SEQ ID NO:330), Figure 136 (SEQ ID NO:337), Figure 139 (SEQ ID NO:346), Figure 142 (SEQ ID NO:352), Figure 145 (SEQ ID NO:358), Figure 147 (SEQ ID NO:363), Figure 149 (SEQ ID NO:370), Figure 151 (SEQ ID NO:375), Figure 153 (SEQ ID NO:380), Figure 155 (SEQ ID NO:385), Figure 157 (SEQ ID NO:390), Figure 159 (SEQ ID NO:395), Figure 161 (SEQ ID NO:400), Figure 163 (SEQ ID NO:405), Figure 165 (SEQ ID NO:410), Figure 167 (SEQ ID NO:415), Figure 169 (SEQ ID NO:420), Figure 171 (SEQ ID NO:425), Figure 173 (SEQ ID NO:430), Figure 177 (SEQ ID NO:437), Figure 179 (SEQ ID NO:442), Figure 181 (SEQ ID NO:447), Figure 183 (SEQ ID NO:452), Figure 185 (SEQ ID NO:454), Figure 187 (SEQ ID NO:456), Figure 190 (SEQ ID NO:459), Figure 192 (SEQ ID NO:464), Figure 194 (SEQ ID NO:466), Figure 196 (SEQ ID NO:468), Figure 198 (SEQ ID NO:470), Figure 200 (SEQ ID NO:472), Figure 202 (SEQ ID NO:477), Figure 204 (SEQ ID NO:483), Figure 207 (SEQ ID NO:488), Figure 209 (SEQ ID NO:496), Figure 211 (SEQ ID NO:498), Figure 213 (SEQ ID NO:506), Figure 215 (SEQ ID NO:508), Figure 217 (SEQ ID NO:510), Figure 219 (SEQ ID NO:515), Figure 222 (SEQ ID NO:523), Figure 225 (SEQ ID NO:526), Figure 230 (SEQ ID NO:612), Figure 232 (SEQ ID NO:614), Figure 234 (SEQ ID NO:616) and Figure 236 (SEQ ID NO:618).

13. An isolated polypeptide scoring at least 80% positives when compared to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36),



ATCC 209866, ATCC 209857, ATCC 209870, ATCC 209859, ATCC 209653, ATCC 209389, ATCC 209386, ATCC 203242, ATCC 203243, ATCC 209783, ATCC 209487, ATCC 209680, 240-PTA or ATCC 209773.

15. A chimeric molecule comprising a polypeptide according to any one of Claims 12 to 14 fused to a heterologous amino acid sequence.

16. The chimeric molecule of Claim 15, wherein said heterologous amino acid sequence is an epitope tag sequence.

17. The chimeric molecule of Claim 15, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

18. An antibody which specifically binds to a polypeptide according to any one of Claims 12 to 14.

19. The antibody of Claim 18, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

20. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36), Figure 20 (SEQ ID NO:45), Figure 22 (SEQ ID NO:52), Figure 24 (SEQ ID NO:59), Figure 26 (SEQ ID NO:64), Figure 28 (SEQ ID NO:69), Figure 30 (SEQ ID NO:74), Figure 33 (SEQ ID NO:85), Figure 35 (SEQ ID NO:90), Figure 37 (SEQ ID NO:97), Figure 39 (SEQ ID NO:102), Figure 41 (SEQ ID NO:109), Figure 43 (SEQ ID NO:114), Figure 45 (SEQ ID NO:119), Figure 47 (SEQ ID NO:124), Figure 49 (SEQ ID NO:132), Figure 51 (SEQ ID NO:137), Figure 53 (SEQ ID NO:145), Figure 55 (SEQ ID NO:150), Figure 59 (SEQ ID NO:157), Figure 61 (SEQ ID NO:162), Figure 63 (SEQ ID NO:169), Figure 66 (SEQ ID NO:178), Figure 68 (SEQ ID NO:183), Figure 70 (SEQ ID NO:190), Figure 73 (SEQ ID NO:196), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:211), Figure 79 (SEQ ID NO:216), Figure 81 (SEQ ID NO:221), Figure 83 (SEQ ID NO:226), Figure 85 (SEQ ID NO:231), Figure 87 (SEQ ID NO:236), Figure 89 (SEQ ID NO:245), Figure 91 (SEQ ID NO:254), Figure 93 (SEQ ID NO:259), Figure 95 (SEQ ID NO:264), Figure 98 (SEQ ID NO:270), Figure 109 (SEQ ID NO:284), Figure 118 (SEQ ID NO:296), Figure 120 (SEQ ID NO:301), Figure 122 (SEQ ID NO:303), Figure 125 (SEQ ID NO:309), Figure 129 (SEQ ID NO:322), Figure 132 (SEQ ID NO:330), Figure 136 (SEQ ID NO:337), Figure 139 (SEQ ID NO:346), Figure 142 (SEQ ID NO:352), Figure 145 (SEQ ID NO:358), Figure 147 (SEQ ID NO:363), Figure 149 (SEQ ID NO:370), Figure 151 (SEQ ID NO:375), Figure 153 (SEQ ID NO:380), Figure 155 (SEQ ID NO:385), Figure 157 (SEQ ID NO:390), Figure 159 (SEQ ID NO:395), Figure 161 (SEQ ID NO:400), Figure 163 (SEQ ID NO:405), Figure 165 (SEQ ID NO:410), Figure 167 (SEQ ID NO:415), Figure 169 (SEQ ID NO:420), Figure 171 (SEQ ID NO:425), Figure 173 (SEQ ID NO:430), Figure 177 (SEQ ID NO:437), Figure 179 (SEQ ID NO:442), Figure 181 (SEQ ID NO:447),

Figure 183 (SEQ ID NO:452), Figure 185 (SEQ ID NO:454), Figure 187 (SEQ ID NO:456), Figure 190 (SEQ ID NO:459), Figure 192 (SEQ ID NO:464), Figure 194 (SEQ ID NO:466), Figure 196 (SEQ ID NO:468), Figure 198 (SEQ ID NO:470), Figure 200 (SEQ ID NO:472), Figure 202 (SEQ ID NO:477), Figure 204 (SEQ ID NO:483), Figure 207 (SEQ ID NO:488), Figure 209 (SEQ ID NO:496), Figure 211 (SEQ ID NO:498), Figure 213 (SEQ ID NO:506), Figure 215 (SEQ ID NO:508), Figure 217 (SEQ ID NO:510), Figure 219 (SEQ ID NO:515), Figure 222 (SEQ ID NO:523), Figure 225 (SEQ ID NO:526), Figure 230 (SEQ ID NO:612), Figure 232 (SEQ ID NO:614), Figure 234 (SEQ ID NO:616) or Figure 236 (SEQ ID NO:618), lacking its associated signal peptide;

(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36), Figure 20 (SEQ ID NO:45), Figure 22 (SEQ ID NO:52), Figure 24 (SEQ ID NO:59), Figure 26 (SEQ ID NO:64), Figure 28 (SEQ ID NO:69), Figure 30 (SEQ ID NO:74), Figure 33 (SEQ ID NO:85), Figure 35 (SEQ ID NO:90), Figure 37 (SEQ ID NO:97), Figure 39 (SEQ ID NO:102), Figure 41 (SEQ ID NO:109), Figure 43 (SEQ ID NO:114), Figure 45 (SEQ ID NO:119), Figure 47 (SEQ ID NO:124), Figure 49 (SEQ ID NO:132), Figure 51 (SEQ ID NO:137), Figure 53 (SEQ ID NO:145), Figure 55 (SEQ ID NO:150), Figure 59 (SEQ ID NO:157), Figure 61 (SEQ ID NO:162), Figure 63 (SEQ ID NO:169), Figure 66 (SEQ ID NO:178), Figure 68 (SEQ ID NO:183), Figure 70 (SEQ ID NO:190), Figure 73 (SEQ ID NO:196), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:211), Figure 79 (SEQ ID NO:216), Figure 81 (SEQ ID NO:221), Figure 83 (SEQ ID NO:226), Figure 85 (SEQ ID NO:231), Figure 87 (SEQ ID NO:236), Figure 89 (SEQ ID NO:245), Figure 91 (SEQ ID NO:254), Figure 93 (SEQ ID NO:259), Figure 95 (SEQ ID NO:264), Figure 98 (SEQ ID NO:270), Figure 109 (SEQ ID NO:284), Figure 118 (SEQ ID NO:296), Figure 120 (SEQ ID NO:301), Figure 122 (SEQ ID NO:303), Figure 125 (SEQ ID NO:309), Figure 129 (SEQ ID NO:322), Figure 132 (SEQ ID NO:330), Figure 136 (SEQ ID NO:337), Figure 139 (SEQ ID NO:346), Figure 142 (SEQ ID NO:352), Figure 145 (SEQ ID NO:358), Figure 147 (SEQ ID NO:363), Figure 149 (SEQ ID NO:370), Figure 151 (SEQ ID NO:375), Figure 153 (SEQ ID NO:380), Figure 155 (SEQ ID NO:385), Figure 157 (SEQ ID NO:390), Figure 159 (SEQ ID NO:395), Figure 161 (SEQ ID NO:400), Figure 163 (SEQ ID NO:405), Figure 165 (SEQ ID NO:410), Figure 167 (SEQ ID NO:415), Figure 169 (SEQ ID NO:420), Figure 171 (SEQ ID NO:425), Figure 173 (SEQ ID NO:430), Figure 177 (SEQ ID NO:437), Figure 179 (SEQ ID NO:442), Figure 181 (SEQ ID NO:447), Figure 183 (SEQ ID NO:452), Figure 185 (SEQ ID NO:454), Figure 187 (SEQ ID NO:456), Figure 190 (SEQ ID NO:459), Figure 192 (SEQ ID NO:464), Figure 194 (SEQ ID NO:466), Figure 196 (SEQ ID NO:468), Figure 198 (SEQ ID NO:470), Figure 200 (SEQ ID NO:472), Figure 202 (SEQ ID NO:477), Figure 204 (SEQ ID NO:483), Figure 207 (SEQ ID NO:488), Figure 209 (SEQ ID NO:496), Figure 211 (SEQ ID NO:498), Figure 213 (SEQ ID NO:506), Figure 215 (SEQ ID NO:508), Figure 217 (SEQ ID NO:510), Figure 219 (SEQ ID NO:515), Figure 222 (SEQ ID NO:523), Figure 225 (SEQ ID NO:526), Figure 230 (SEQ ID NO:612), Figure 232 (SEQ ID NO:614), Figure 234 (SEQ ID NO:616) or Figure 236 (SEQ ID NO:618), with its associated signal peptide; or

(c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36), Figure 20 (SEQ ID NO:45), Figure 22 (SEQ ID NO:52), Figure 24 (SEQ ID NO:59), Figure

26 (SEQ ID NO:64), Figure 28 (SEQ ID NO:69), Figure 30 (SEQ ID NO:74), Figure 33 (SEQ ID NO:85), Figure 35 (SEQ ID NO:90), Figure 37 (SEQ ID NO:97), Figure 39 (SEQ ID NO:102), Figure 41 (SEQ ID NO:109), Figure 43 (SEQ ID NO:114), Figure 45 (SEQ ID NO:119), Figure 47 (SEQ ID NO:124), Figure 49 (SEQ ID NO:132), Figure 51 (SEQ ID NO:137), Figure 53 (SEQ ID NO:145), Figure 55 (SEQ ID NO:150), Figure 59 (SEQ ID NO:157), Figure 61 (SEQ ID NO:162), Figure 63 (SEQ ID NO:169), Figure 66 (SEQ ID NO:178), Figure 68 (SEQ ID NO:183), Figure 70 (SEQ ID NO:190), Figure 73 (SEQ ID NO:196), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:211), Figure 79 (SEQ ID NO:216), Figure 81 (SEQ ID NO:221), Figure 83 (SEQ ID NO:226), Figure 85 (SEQ ID NO:231), Figure 87 (SEQ ID NO:236), Figure 89 (SEQ ID NO:245), Figure 91 (SEQ ID NO:254), Figure 93 (SEQ ID NO:259), Figure 95 (SEQ ID NO:264), Figure 98 (SEQ ID NO:270), Figure 109 (SEQ ID NO:284), Figure 118 (SEQ ID NO:296), Figure 120 (SEQ ID NO:301), Figure 122 (SEQ ID NO:303), Figure 125 (SEQ ID NO:309), Figure 129 (SEQ ID NO:322), Figure 132 (SEQ ID NO:330), Figure 136 (SEQ ID NO:337), Figure 139 (SEQ ID NO:346), Figure 142 (SEQ ID NO:352), Figure 145 (SEQ ID NO:358), Figure 147 (SEQ ID NO:363), Figure 149 (SEQ ID NO:370), Figure 151 (SEQ ID NO:375), Figure 153 (SEQ ID NO:380), Figure 155 (SEQ ID NO:385), Figure 157 (SEQ ID NO:390), Figure 159 (SEQ ID NO:395), Figure 161 (SEQ ID NO:400), Figure 163 (SEQ ID NO:405), Figure 165 (SEQ ID NO:410), Figure 167 (SEQ ID NO:415), Figure 169 (SEQ ID NO:420), Figure 171 (SEQ ID NO:425), Figure 173 (SEQ ID NO:430), Figure 177 (SEQ ID NO:437), Figure 179 (SEQ ID NO:442), Figure 181 (SEQ ID NO:447), Figure 183 (SEQ ID NO:452), Figure 185 (SEQ ID NO:454), Figure 187 (SEQ ID NO:456), Figure 190 (SEQ ID NO:459), Figure 192 (SEQ ID NO:464), Figure 194 (SEQ ID NO:466), Figure 196 (SEQ ID NO:468), Figure 198 (SEQ ID NO:470), Figure 200 (SEQ ID NO:472), Figure 202 (SEQ ID NO:477), Figure 204 (SEQ ID NO:483), Figure 207 (SEQ ID NO:488), Figure 209 (SEQ ID NO:496), Figure 211 (SEQ ID NO:498), Figure 213 (SEQ ID NO:506), Figure 215 (SEQ ID NO:508), Figure 217 (SEQ ID NO:510), Figure 219 (SEQ ID NO:515), Figure 222 (SEQ ID NO:523), Figure 225 (SEQ ID NO:526), Figure 230 (SEQ ID NO:612), Figure 232 (SEQ ID NO:614), Figure 234 (SEQ ID NO:616) or Figure 236 (SEQ ID NO:618), lacking its associated signal peptide.

21. An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36), Figure 20 (SEQ ID NO:45), Figure 22 (SEQ ID NO:52), Figure 24 (SEQ ID NO:59), Figure 26 (SEQ ID NO:64), Figure 28 (SEQ ID NO:69), Figure 30 (SEQ ID NO:74), Figure 33 (SEQ ID NO:85), Figure 35 (SEQ ID NO:90), Figure 37 (SEQ ID NO:97), Figure 39 (SEQ ID NO:102), Figure 41 (SEQ ID NO:109), Figure 43 (SEQ ID NO:114), Figure 45 (SEQ ID NO:119), Figure 47 (SEQ ID NO:124), Figure 49 (SEQ ID NO:132), Figure 51 (SEQ ID NO:137), Figure 53 (SEQ ID NO:145), Figure 55 (SEQ ID NO:150), Figure 59 (SEQ ID NO:157), Figure 61 (SEQ ID NO:162), Figure 63 (SEQ ID NO:169), Figure 66 (SEQ ID NO:178), Figure 68 (SEQ ID NO:183), Figure 70 (SEQ ID NO:190), Figure 73 (SEQ ID NO:196), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:211), Figure 79 (SEQ ID NO:216), Figure 81 (SEQ ID NO:221), Figure 83 (SEQ ID NO:226), Figure 85 (SEQ ID NO:231), Figure 87 (SEQ ID NO:236), Figure 89 (SEQ ID NO:245), Figure 91 (SEQ ID NO:254), Figure 93 (SEQ ID NO:259), Figure 95 (SEQ ID NO:264), Figure 98 (SEQ ID NO:270), Figure 109 (SEQ ID NO:284), Figure



118 (SEQ ID NO:296), Figure 120 (SEQ ID NO:301), Figure 122 (SEQ ID NO:303), Figure 125 (SEQ ID NO:309), Figure 129 (SEQ ID NO:322), Figure 132 (SEQ ID NO:330), Figure 136 (SEQ ID NO:337), Figure 139 (SEQ ID NO:346), Figure 142 (SEQ ID NO:352), Figure 145 (SEQ ID NO:358), Figure 147 (SEQ ID NO:363), Figure 149 (SEQ ID NO:370), Figure 151 (SEQ ID NO:375), Figure 153 (SEQ ID NO:380), Figure 155 (SEQ ID NO:385), Figure 157 (SEQ ID NO:390), Figure 159 (SEQ ID NO:395), Figure 161 (SEQ ID NO:400), Figure 163 (SEQ ID NO:405), Figure 165 (SEQ ID NO:410), Figure 167 (SEQ ID NO:415), Figure 169 (SEQ ID NO:420), Figure 171 (SEQ ID NO:425), Figure 173 (SEQ ID NO:430), Figure 177 (SEQ ID NO:437), Figure 179 (SEQ ID NO:442), Figure 181 (SEQ ID NO:447), Figure 183 (SEQ ID NO:452), Figure 185 (SEQ ID NO:454), Figure 187 (SEQ ID NO:456), Figure 190 (SEQ ID NO:459), Figure 192 (SEQ ID NO:464), Figure 194 (SEQ ID NO:466), Figure 196 (SEQ ID NO:468), Figure 198 (SEQ ID NO:470), Figure 200 (SEQ ID NO:472), Figure 202 (SEQ ID NO:477), Figure 204 (SEQ ID NO:483), Figure 207 (SEQ ID NO:488), Figure 209 (SEQ ID NO:496), Figure 211 (SEQ ID NO:498), Figure 213 (SEQ ID NO:506), Figure 215 (SEQ ID NO:508), Figure 217 (SEQ ID NO:510), Figure 219 (SEQ ID NO:515), Figure 222 (SEQ ID NO:523), Figure 225 (SEQ ID NO:526), Figure 230 (SEQ ID NO:612), Figure 232 (SEQ ID NO:614), Figure 234 (SEQ ID NO:616) or Figure 236 (SEQ ID NO:618), lacking its associated signal peptide;

(b) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36), Figure 20 (SEQ ID NO:45), Figure 22 (SEQ ID NO:52), Figure 24 (SEQ ID NO:59), Figure 26 (SEQ ID NO:64), Figure 28 (SEQ ID NO:69), Figure 30 (SEQ ID NO:74), Figure 33 (SEQ ID NO:85), Figure 35 (SEQ ID NO:90), Figure 37 (SEQ ID NO:97), Figure 39 (SEQ ID NO:102), Figure 41 (SEQ ID NO:109), Figure 43 (SEQ ID NO:114), Figure 45 (SEQ ID NO:119), Figure 47 (SEQ ID NO:124), Figure 49 (SEQ ID NO:132), Figure 51 (SEQ ID NO:137), Figure 53 (SEQ ID NO:145), Figure 55 (SEQ ID NO:150), Figure 59 (SEQ ID NO:157), Figure 61 (SEQ ID NO:162), Figure 63 (SEQ ID NO:169), Figure 66 (SEQ ID NO:178), Figure 68 (SEQ ID NO:183), Figure 70 (SEQ ID NO:190), Figure 73 (SEQ ID NO:196), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:211), Figure 79 (SEQ ID NO:216), Figure 81 (SEQ ID NO:221), Figure 83 (SEQ ID NO:226), Figure 85 (SEQ ID NO:231), Figure 87 (SEQ ID NO:236), Figure 89 (SEQ ID NO:245), Figure 91 (SEQ ID NO:254), Figure 93 (SEQ ID NO:259), Figure 95 (SEQ ID NO:264), Figure 98 (SEQ ID NO:270), Figure 109 (SEQ ID NO:284), Figure 118 (SEQ ID NO:296), Figure 120 (SEQ ID NO:301), Figure 122 (SEQ ID NO:303), Figure 125 (SEQ ID NO:309), Figure 129 (SEQ ID NO:322), Figure 132 (SEQ ID NO:330), Figure 136 (SEQ ID NO:337), Figure 139 (SEQ ID NO:346), Figure 142 (SEQ ID NO:352), Figure 145 (SEQ ID NO:358), Figure 147 (SEQ ID NO:363), Figure 149 (SEQ ID NO:370), Figure 151 (SEQ ID NO:375), Figure 153 (SEQ ID NO:380), Figure 155 (SEQ ID NO:385), Figure 157 (SEQ ID NO:390), Figure 159 (SEQ ID NO:395), Figure 161 (SEQ ID NO:400), Figure 163 (SEQ ID NO:405), Figure 165 (SEQ ID NO:410), Figure 167 (SEQ ID NO:415), Figure 169 (SEQ ID NO:420), Figure 171 (SEQ ID NO:425), Figure 173 (SEQ ID NO:430), Figure 177 (SEQ ID NO:437), Figure 179 (SEQ ID NO:442), Figure 181 (SEQ ID NO:447), Figure 183 (SEQ ID NO:452), Figure 185 (SEQ ID NO:454), Figure 187 (SEQ ID NO:456), Figure 190 (SEQ ID NO:459), Figure 192 (SEQ ID NO:464), Figure 194 (SEQ ID NO:466), Figure 196 (SEQ ID NO:468), Figure 198 (SEQ ID NO:470), Figure 200 (SEQ ID NO:472), Figure 202 (SEQ ID NO:477), Figure 204 (SEQ ID NO:483), Figure 207 (SEQ ID NO:488), Figure 209 (SEQ ID NO:496), Figure 211 (SEQ ID NO:498), Figure 213 (SEQ ID

NO:506), Figure 215 (SEQ ID NO:508), Figure 217 (SEQ ID NO:510), Figure 219 (SEQ ID NO:515), Figure 222 (SEQ ID NO:523), Figure 225 (SEQ ID NO:526), Figure 230 (SEQ ID NO:612), Figure 232 (SEQ ID NO:614), Figure 234 (SEQ ID NO:616) or Figure 236 (SEQ ID NO:618), with its associated signal peptide; or

(c) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:7), Figure 9 (SEQ ID NO:19), Figure 11 (SEQ ID NO:28), Figure 15 (SEQ ID NO:36), Figure 20 (SEQ ID NO:45), Figure 22 (SEQ ID NO:52), Figure 24 (SEQ ID NO:59), Figure 26 (SEQ ID NO:64), Figure 28 (SEQ ID NO:69), Figure 30 (SEQ ID NO:74), Figure 33 (SEQ ID NO:85), Figure 35 (SEQ ID NO:90), Figure 37 (SEQ ID NO:97), Figure 39 (SEQ ID NO:102), Figure 41 (SEQ ID NO:109), Figure 43 (SEQ ID NO:114), Figure 45 (SEQ ID NO:119), Figure 47 (SEQ ID NO:124), Figure 49 (SEQ ID NO:132), Figure 51 (SEQ ID NO:137), Figure 53 (SEQ ID NO:145), Figure 55 (SEQ ID NO:150), Figure 59 (SEQ ID NO:157), Figure 61 (SEQ ID NO:162), Figure 63 (SEQ ID NO:169), Figure 66 (SEQ ID NO:178), Figure 68 (SEQ ID NO:183), Figure 70 (SEQ ID NO:190), Figure 73 (SEQ ID NO:196), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:211), Figure 79 (SEQ ID NO:216), Figure 81 (SEQ ID NO:221), Figure 83 (SEQ ID NO:226), Figure 85 (SEQ ID NO:231), Figure 87 (SEQ ID NO:236), Figure 89 (SEQ ID NO:245), Figure 91 (SEQ ID NO:254), Figure 93 (SEQ ID NO:259), Figure 95 (SEQ ID NO:264), Figure 98 (SEQ ID NO:270), Figure 109 (SEQ ID NO:284), Figure 118 (SEQ ID NO:296), Figure 120 (SEQ ID NO:301), Figure 122 (SEQ ID NO:303), Figure 125 (SEQ ID NO:309), Figure 129 (SEQ ID NO:322), Figure 132 (SEQ ID NO:330), Figure 136 (SEQ ID NO:337), Figure 139 (SEQ ID NO:346), Figure 142 (SEQ ID NO:352), Figure 145 (SEQ ID NO:358), Figure 147 (SEQ ID NO:363), Figure 149 (SEQ ID NO:370), Figure 151 (SEQ ID NO:375), Figure 153 (SEQ ID NO:380), Figure 155 (SEQ ID NO:385), Figure 157 (SEQ ID NO:390), Figure 159 (SEQ ID NO:395), Figure 161 (SEQ ID NO:400), Figure 163 (SEQ ID NO:405), Figure 165 (SEQ ID NO:410), Figure 167 (SEQ ID NO:415), Figure 169 (SEQ ID NO:420), Figure 171 (SEQ ID NO:425), Figure 173 (SEQ ID NO:430), Figure 177 (SEQ ID NO:437), Figure 179 (SEQ ID NO:442), Figure 181 (SEQ ID NO:447), Figure 183 (SEQ ID NO:452), Figure 185 (SEQ ID NO:454), Figure 187 (SEQ ID NO:456), Figure 190 (SEQ ID NO:459), Figure 192 (SEQ ID NO:464), Figure 194 (SEQ ID NO:466), Figure 196 (SEQ ID NO:468), Figure 198 (SEQ ID NO:470), Figure 200 (SEQ ID NO:472), Figure 202 (SEQ ID NO:477), Figure 204 (SEQ ID NO:483), Figure 207 (SEQ ID NO:488), Figure 209 (SEQ ID NO:496), Figure 211 (SEQ ID NO:498), Figure 213 (SEQ ID NO:506), Figure 215 (SEQ ID NO:508), Figure 217 (SEQ ID NO:510), Figure 219 (SEQ ID NO:515), Figure 222 (SEQ ID NO:523), Figure 225 (SEQ ID NO:526), Figure 230 (SEQ ID NO:612), Figure 232 (SEQ ID NO:614), Figure 234 (SEQ ID NO:616) or Figure 236 (SEQ ID NO:618), lacking its associated signal peptide.

22. A method of detecting a PRO4993 polypeptide in a sample suspected of containing a PRO4993 polypeptide, said method comprising contacting said sample with a PRO337 polypeptide and determining the formation of a PRO4993/PRO337 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO4993 polypeptide in said sample.

23. The method according to Claim 22, wherein said sample comprises cells suspected of expressing said PRO4993 polypeptide.

24. The method according to Claim 22, wherein said PRO337 polypeptide is labeled with a detectable label.

25. The method according to Claim 22, wherein said PRO337 polypeptide is attached to a solid support.

26. A method of detecting a PRO337 polypeptide in a sample suspected of containing a PRO337 polypeptide, said method comprising contacting said sample with a PRO4993 polypeptide and determining the formation of a PRO4993/PRO337 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO337 polypeptide in said sample.

27. The method according to Claim 26, wherein said sample comprises cells suspected of expressing said PRO337 polypeptide.

28. The method according to Claim 26, wherein said PRO4993 polypeptide is labeled with a detectable label.

29. The method according to Claim 26, wherein said PRO4993 polypeptide is attached to a solid support.

30. A method of detecting a PRO1559 polypeptide in a sample suspected of containing a PRO1559 polypeptide, said method comprising contacting said sample with a PRO725, PRO700 or PRO739 polypeptide and determining the formation of a PRO1559/PRO725, PRO700 or PRO739 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1559 polypeptide in said sample.

31. The method according to Claim 30, wherein said sample comprises cells suspected of expressing said PRO1559 polypeptide.

32. The method according to Claim 30, wherein said PRO725, PRO700 or PRO739 polypeptide is labeled with a detectable label.

33. The method according to Claim 30, wherein said PRO725, PRO700 or PRO739 polypeptide is attached to a solid support.

34. A method of detecting a PRO725, PRO700 or PRO739 polypeptide in a sample suspected of containing a PRO725, PRO700 or PRO739 polypeptide, said method comprising contacting said sample with a PRO1559 polypeptide and determining the formation of a PRO1559/PRO725, PRO700 or PRO739 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO725,

PRO700 or PRO739 polypeptide in said sample.

35. The method according to Claim 34, wherein said sample comprises cells suspected of expressing said PRO725, PRO700 or PRO739 polypeptide.

5 36. The method according to Claim 34, wherein said PRO1559 polypeptide is labeled with a detectable label.

37. The method according to Claim 34, wherein said PRO1559 polypeptide is attached to a solid support.

10 38. A method of linking a bioactive molecule to a cell expressing a PRO337 polypeptide, said method comprising contacting said cell with a PRO4993 polypeptide that is bound to said bioactive molecule and allowing said PRO337 and PRO4993 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

15 39. The method according to Claim 38, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

20 40. The method according to Claim 38, wherein said bioactive molecule causes the death of said cell.

25 41. A method of linking a bioactive molecule to a cell expressing a PRO4993 polypeptide, said method comprising contacting said cell with a PRO337 polypeptide that is bound to said bioactive molecule and allowing said PRO4993 and PRO337 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

30 42. The method according to Claim 41, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

43. The method according to Claim 41, wherein said bioactive molecule causes the death of said cell.

35 44. A method of linking a bioactive molecule to a cell expressing a PRO1559 polypeptide, said method comprising contacting said cell with a PRO725, PRO700 or PRO739 polypeptide that is bound to said bioactive molecule and allowing said PRO1559 and PRO725, PRO700 or PRO739 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

45. The method according to Claim 44, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

46. The method according to Claim 44, wherein said bioactive molecule causes the death of said cell.

47. A method of linking a bioactive molecule to a cell expressing a PRO725, PRO700 or PRO739 polypeptide, said method comprising contacting said cell with a PRO1559 polypeptide that is bound to said bioactive molecule and allowing said PRO1559 and PRO725, PRO700 or PRO739 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

48. The method according to Claim 47, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

49. The method according to Claim 47, wherein said bioactive molecule causes the death of said cell.

50. A method of modulating at least one biological activity of a cell expressing a PRO337 polypeptide, said method comprising contacting said cell with a PRO4993 polypeptide or an anti-PRO337 antibody, whereby said PRO4993 polypeptide or said anti-PRO337 antibody binds to said PRO337 polypeptide, thereby modulating at least one biological activity of said cell.

51. The method according to Claim 50, wherein said cell is killed.

52. A method of modulating at least one biological activity of a cell expressing a PRO4993 polypeptide, said method comprising contacting said cell with a PRO337 polypeptide or an anti-PRO4993 antibody, whereby said PRO337 polypeptide or said anti-PRO4993 antibody binds to said PRO4993 polypeptide, thereby modulating at least one biological activity of said cell.

53. The method according to Claim 52, wherein said cell is killed.

54. A method of modulating at least one biological activity of a cell expressing a PRO1559 polypeptide, said method comprising contacting said cell with a PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 antibody, whereby said PRO725, PRO700 or PRO739 polypeptide or said anti-PRO1559 antibody binds to said PRO1559 polypeptide, thereby modulating at least one biological activity of said cell.

55. The method according to Claim 54, wherein said cell is killed.

56. A method of modulating at least one biological activity of a cell expressing a PRO725, PRO700 or PRO739 polypeptide, said method comprising contacting said cell with a PRO1559 polypeptide or an anti-PRO725, anti-PRO700 or anti-PRO739 antibody, whereby said PRO1559 polypeptide or said anti-PRO725, anti-PRO700 or anti-PRO739 antibody binds to said PRO725, PRO700 or PRO739 polypeptide, thereby modulating at least one biological activity of said cell.

57. The method according to Claim 56, wherein said cell is killed.